Business · 30/04/2007Updated: 10/17/2026 · 1 min read
FDA and National Cancer Institute Collaborate on Proteomics Science
Summary
The FDA and National Cancer Institute have signed a Memorandum of Understanding to accelerate the development and application of proteomics technology in clinical settings, focusing on areas such as biomarker discovery and validation, sample collection, and data analysis.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →